3-[2-(4-Bromphenyl)hydrazono]-5-phenyl-furan-2(3H)-one (1) was used for preparation of some novel pyrazole, pyridazinone, oxadiazole, triazole, thiazolidine and thioxopyrimidine derivatives. Some of the prepared products were tested for anti-avian influenza virus activity and revealed promising antiviral activity against H5N1 virus [A/Chicken/Egypt/1/20 % (H5N1)] by determination of both EC 50 and LD 50 and confirmed by plaque reduction assay on Madin-Darby canine kidney cells. Compounds 3-[2-(4-bromophenyl)hydrazono]-5-phenylfuran--2(3H)-one (1), 1-(4-bromophenyl)-N-hydroxy-5-phenyl--1H-pyrazole-3-carboxamide (5) and 1-(4-bromophenyl)--N-{2,3-dihydro-4-hydroxy-3-phenyl-6-oxo-2-thioxopyrimidin-1(6H)-yl}-5-phenyl-1H-pyrazole-3-carboxamide (12a) showed the highest effects. Detailed synthesis, spectroscopic data, and antiviral activity of the synthesized compounds are reported.
Keywords: furanone, pyrazole, pyridazinone, oxadiazole, triazole, anti-avian influenza virus (H5N1) acetic transaminase (GOT) and glutamate pyruvate transaminase (GPT) enzymes, inhibition of gamma-glutamyl transpeptidase (g-GT) enzyme activity (9) and potent inhibition of tyrosine (10) . On the other hand, substituted 1,3,4-oxadiazoles exhibit fungicidal (11) , antimicrobial and antitubercular activity (12) . Simple 1,2,4-triazoles also display some biological activities as antioxidant, urease inhibitors (13) and antiviral (14) agents. These diverse pharmacological activities prompted us to convert furanone into other heterocycles bearing pyrazolyl moiety, and evaluate them for anti-viral activity. On the other hand, influenza viruses are respiratory pathogens that affect humans and are responsible for substantial morbidity, mortality and decreased productivity worldwide (15) . Several synthetic compounds have already been utilized as potential inhibitors of the avian virus (H5N1) and some of them demonstrated the ability to inhibit viral replication at a level comparable to the approved anti-influenza drugs zanamivir and oseltamivir (16) .
EXPERIMENTAL
Melting points were measured using an Electrothermal 9100 digital melting point apparatus (Büchi, Switzerland) and are uncorrected. IR spectra were recorded on a Perkin-Elmer 1600 FTIR (Perkin-Elmer, USA) in KBr discs. 1 H NMR spectra were measured on a Jeol 270 MHz spectrometer (Jeol, Japan) and a Bruker Avance spectrometer (300 MHz) (Bruker, Germany) in DMSO-d 6 , and chemical shifts were recorded in d ppm relative to the internal standard TMS. Mass spectra were run at 70 eV with a Finnigan SSQ 7000 spectrometer (Thermo electron corporation, USA) using EI; m/z values are indicated in Dalton. Elemental analyses were performed on a Perkin-Elmer 2400 analyzer (Perkin-Elmer) and were found within ±0.4 % of the theoretical values (Table I) . Follow-up of the reactions and checking of the purity of compounds were done by TLC on silica gel-precoted aluminum sheets (type 60 F 254 , Merck, Germany). All solvents and reagents were purchased from Aldrich (Germany).
Physicochemical and spectral data for the synthesized compounds are given in Tables I and II, respectively.
Syntheses 3-[2-(4-Bromophenyl)hydrazono]-5-phenylfuran-2(3H)-one (1).
-To a solution of bromoaniline (6.88 g, 0.04 mol) in glacial acetic acid (15 mL), conc. HCl (8 mL) was added, then while the mixture was being cooled in ice under stirring, sodium nitrite (4.96 g, 0.068 mol) was added dropwise. To the diazonium mixture, freshly fused sodium acetate (6.0 g) was added. Aroyl propionic acid (6.0 g, 0.04 mol) was added to acetic anhydride (40 mL), the mixture was refluxed for 3 h, then allowed to cool at room temperature. This solution was added dropwise, with stirring and cooling in ice, to the diazo-nium mixture. The reaction mixture was allowed to stand overnight and the precipitate was collected, washed with water several times and recrystallized from acetic acid to give high yield (2). (2) . -A mixture of furanone 1 (3.42 g, 0.01 mol) and hydrazine hydrate (0.64 g, 0.02 mol, 98 %) in absolute ethanol (20 mL), was stirred at room temperature for 0.5 h. The solvent was evaporated under vacuum and crystals were obtained. (3) . -A mixture of furanone 1 (3.42 g, 0.01 mol) and hydrazine hydrate 98 % (0.64 g, 0.02 mol) in absolute ethanol (25 mL) was refluxed for 2 h. The solvent was evaporated under vacuum and the solid residue was recrystallized from benzene. (4) . -A mixture of furanone 1 (3.42 g, 0.01 mol) and phenylhydrazine (1.3 g, 0.012 mol) in absolute ethanol (25 mL) was refluxed for 3 h. The solvent was evaporated under vacuum and the solid residue was recrystallized from benzene/petroleum ether (60-80°C, 1:1).
2-[2-(4-Bromophenyl)hydrazono]-4-oxo-4-phenylbutane hydrazide

4-[2-(4-Bromophenyl)hydrazinyl]-6-phenylpyridazin-3(2H) one
4-[2-(4-Bromophenyl
)hydrazono]-1,2-dihydro-1,6-diphenylpyridazin-3(4H)-one
1-(4-Bromophenyl)-N-hydroxy-5-phenyl-1H-pyrazole-3-carboxamide (5).
-A mixture of furanone 1 (3.42 g, 0.01 mol), hydroxylamine hydrochloride (0.7 g, 0.01 mol) and sodium acetate (1 g) in ethanol (25 mL) was refluxed for 4 h. The solvent was evaporated under vacuum and the solid residue was recrystallized from benzene/petroleum ether (60-80°C , 1:1).
5-[1-(4-Bromophenyl)-5-phenyl-1H-pyrazole-3-yl]-1,3,4-oxadiazole-2(3H)-thione (6)
. -A mixture of hydrazide 2 (1.13 g, 0.003 mol), carbon disulfide (5 mL) and sodium hydroxide (4 %, 3 mL) in ethanol (30 mL) was stirred at room temperature for 6 h. The solvent was evaporated under vacuum, dissolved in hot water, and then the filtrate was neutralized with diluted hydrochloric acid. The yellow precipitate was collected after washing with water several times. The product obtained was recrystallized from benzene/petroleum ether (60-80°C, 1:1).
2-{[1-(4-Bromophenyl)-5-aryl-1H-pyrazol-3-yl]carbonyl}-N-phenyl-hydrazinecarbo-thioamides (7a,b
). -A mixture of hydrazides 2 (3.75 g, 0.01 mol) and phenyl or p-methoxyphenyl isothiocyanate (0.01 mol) in ethanol (30 mL), was refluxed for 2 h. The mixture was cooled, and then filtered off. The solid so obtained was recrystallized from benzene/ethanol (1:2.5).
1-(4-
-To a suspension of hydrazide 2 (1.13 g, 0.003 mol) in dry benzene (15 mL), benzoyl chloride (0.42 g, 0.003 mol) was added at 25°C and the mixture was heated under reflux at 75°C for 3 h. The solvent was evaporated under vacuum, and the solid residue was recrystallized from benzene.
2-{1-(4-Bromophenyl)-5-phenyl-1H-pyrazole-3-yl}-5-phenyl-1,3,4-oxadiazole (9)
. -A mixture of diaroylhydrazine 8 (0.92 g, 0.002 mol) and phosphorus oxychloride (10 mL) was refluxed for 1 h. The mixture was cooled, poured onto crushed ice and then neutralized with 4 % NaOH. The white precipitate was collected by filtration, washed with water and recrystallized from benzene.
4-(4-Bromophenyl)-5-(1-aryl-5-phenyl-1H-pyrazol-3-yl)-2H-1,2,4-triazole-3(4H)-thiones (10a,b
). -A mixture of thiosemicarbazides 7a,b (0.001 mol) and NaOH (4 %, 20 mL) was refluxed for 2 h. The mixture was cooled, poured onto crushed ice and then neutralized with diluted hydrochloric acid. The white precipitate was collected by filtration and washed with water. The solid obtained was recrystallized from ethanol/water (5:1). fluxed for 2 h. The solvent was evaporated under reduced pressure; the reaction mixture was poured onto water. The obtained precipitate was filtered off, washed with water, dried and recrystallized from ethanol. 3-carboxamide (12a,b) . -A solution of 7a or b (0.001 mol) in sodium ethoxide (0.023 g sodium metal in 30 mL ethanol) was heated for 30 min at 80°C. The reaction mixture was cooled, and then diethylmalonate (0.016 g, 0.001 mol) was poured into water, with stirring at 70°C for 3 h. The precipitated solid was filtered off, washed with water, dried and recrystallized from methanol to give compounds 12a,b. passaged in Dulbecco's modified Eagle medium (DMEM) containing 10 % fetal bovine serum (FBS) and 1 % antibiotic-antimycotic mixture (penicillin-streptomycin-amphotericin B).
1-(4-Bromophenyl)-N-(4-oxo-3-arylthiazolidine-2-ylidene)-5-phenyl-1H-pyrazole-3-carbohydrazides (11a,b
1-(4-Bromophenyl)-N-{2,3-dihydro-4-hydroxy-3-aryl-6-oxo-2-thioxopyrimidin-1(6H)-yl}--5-phenyl-1H-pyrazole-
Compound preparation for biological assays. -Prepared compounds were dissolved in 10 % dimethyl sulphoxide (DMSO) in doubly destilled water to a concentration of 10 mg mL -1 stock solutions used for further dilutions according to the assay applied.
Cytotoxicity assay (MTT assay). -Cytotoxic activity of the extracts was tested in MDCK cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (17) with minor modification. Briefly, the cells were seeded in 96 well--plates (100 µL per well containing 3 × 10 5 cells mL -1 ) and treated with 5, 10, 20, 40, 80 and 120 µg of the sample per well. At 24 h, cells were washed with sterile phosphate buffer (PBS) three times and the supernatant was discarded. MTT solution (20 µL of 5 mg mL -1 ) was added to each well and incubated at 37°C for 4 h. Then the medium was aspirated. In each well, the formed formazan crystals were dissolved with 200 µL of acidified isopropanol (0.04 mol L -1 HCl in absolute isopropanol). Absorbance of formazan was detected with a dual wavelength UV spectrometer at 540 nm with 620 nm reference wavelength. The percentage of cytotoxicity compared to the untreated cells was determined. The 50 %-cytotoxicity (LD 50 ) for each compound was calculated from standard curve of percentage of cytotoxicity vs. sample concentration.
Antiviral activity and therapeutic index. -Antiviral activity of the compounds was determined using the cytopathogenicity (CPE) assay against low pathogenic reassortant avian influenza virus (rH5N1). Cells were seeded in 96-well cell culture plates (100 µL per well at a density of 3 × 10 5 cells mL -1 ) and grown to confluency. Cells were then infected with 100 µL of stock virus. After the virus adsorption period on cells of 2 hours at 37°C, the virus was removed and serial dilutions (10, 20 , 40 µg µL -1 ) of the tested compounds were added, then incubated with infected cells using maintenance DMEM with 2 % FBS (100 µl per well) at 37°C for 3 days of monitoring until complete CPE was observed in the infected and untreated virus control.
Plaque reduction assay. -In a six-well cell culture plate, confluent MDCK cells were infected with a pre-incubated mixture of 100 µL of avian influenza H5N1 virus (80-100 plaques per well) and 100 µL of DMEM [containing 2 % antibiotics and 1 mg mL -1 of L-1-tosyl-amido-2-phenylethyl chloromethyl ketene and a different concentration of each compound (5, 10, 20, and 40 mg mL -1 )]. The plates were incubated for 1 h at 37°C in 5 % CO 2 to allow virus adsorption. After adsorption, 2 mL of agarose overlayer (2 % agarose in DMEM 2 x containing 1 % FBS) was added to each well and mixed. The cultures were incubated at 37°C in 5 % CO 2 for 3-4 days of plaque formation monitoring. Plaques were fixed with 10 % formalin in phosphate-buffered saline for 2 h followed by removal of the agar overlayer and staining with 0.1 % crystal violet in distilled water. Plaques were counted manually from triplicate wells based on the plaque number but not plaque size. Viral counts and percentage of virus reduction were calculated according to Hayden et al. (18) .
RESULTS AND DISCUSSION
Chemistry
3-[2-(4-Bromophenyl)hydrazono]-5-phenylfuran-2(3H)-one (1) was prepared by coupling the diazotized aniline with 5-phenyl-2(3H)-furanone according to the reported procedures (2). Furanone 1 was reacted with hydrazine hydrate in absolute ethanol at room temperature to give the corresponding acid hydrazide 2, which was refluxed in ethanol to give pyridazinone derivative 3. Also, compound 3 was prepared by refluxing compound 1 with hydrazine hydrate in absolute ethanol. The reaction of furanone 1 with phenylhydrazine was also investigated. When the reaction was carried out under reflux conditions, pyridazinone derivative 4 was formed. Moreover, furanone 1 was reacted with hydroxylamine hydrochloride in ethanol under reflux to give pyrazole derivative 5 (Scheme 1).
Treatment of 2 with carbon disulphide in alcoholic sodium hydroxide gave oxadiazolthione derivative 6. Hydrazide 2 was reacted with phenyl or p-methoxyphenyl isothiocyanate to give the corresponding thiosemicarbazide derivatives 7a,b, respectively. Also, hydrazide 2 was reacted with benzoyl chloride in dry benzene to give the corresponding pyrazole derivative 8, which was treated with phosphorus oxychloride to afford the corresponding 1,3,4-oxadiazole derivative 9 (Scheme 2). Ring closure of thiosemicarbazides 7a,b using sodium hydroxide solution, led to the formation of the corresponding triazolthiones 10a,b. Also, the reaction of thiosemicarbazides 7a,b with ethyl chloroacetate in the presence of alcoholic potassium hydroxide afforded thiazolidine derivatives 11a,b, respectively. Moreover, when thiosemicarbazides 7a,b were reacted with diethylmalonate in the presence of sodium ethoxide, the corresponding thioxopyrimidin derivatives 12a,b were formed (Scheme 3).
Antiviral bioassays
Cytotoxicity assay (MTT) was carried out on all prepared compounds and according to the results obtained, only compounds 1, 5, 7a, 8, 9, 10a, 11a , and 12a showed notable toxic effects on the biology of cells used in assays. The LD 50 , EC 50 , and therapeutic index (TI) are presented in Fig. 1 . Calculated LD 50 value indicated that only 1, 5, 12a passed the antiviral activity bioassay.
It was obvious that at concentrations of 10, 20 and 40 mg mL -1 compounds 1, 5 and 12a showed higher therapeutic indices than the other tested compounds compared to the anti-influenza drug zanamivir. Plaque reduction assay confirmed the antiviral activity of the three compounds as shown in Fig. 2 . 
Structure-activity relationship
Structure modifications on the lead compounds 1 and 2 afforded derivatives with a variety of anti-avian influenza virus (H5N1) activity. For example, pyrazole-3-carboxyamide derivative 5 demonstrated remarkable activity due to the chromophor in the skeleton of this compound and displayed a significant EC 50 value in regard to the parent compound 1 (Fig. 1) . However, product 2 does not appear to be advantageous in terms of anti-avian influenza virus with respect to the parent 1 because of its open chain structure and higher hydrophilicity. Furthermore, chemical transformation/structure conversion of 2 into 7 and 8 influenced positively the activity profiles against influenza virus compared to their parent. On the contrary, a dramatic drop of activity was observed for compound 9 because of the building of the oxazole ring. This behavior confirmed that such functionalization hindered the interaction with the host cell receptor for virus entry and decreased the activity. Transformation of 7a,b into 10a,b and 12a,b was accomplished with significant changes in activity. Increase of activity here can be attributed to the triazole and pyrimidine ring formation. In particular, 10a and 12a showed remarkable activity to the parent 7a whereas a dramatic drop of activity was noted in case of 11a compared to 7a which was probably due to the thiazolidine ring formation. In conclusion, it follows that pyrazole nucleus is essential for anti-avian influenza virus (H5N1) activity; increased number of nitrogen atoms and amide functions sharply increases the activity; open chains containing amide C=O conjugated with pyrazole ring are more active than cyclized ones.
CONCLUSIONS
A series of novel pyrazole, pyridazinone, oxadiazole, triazole, thiazolidine and thioxopyrimidine derivatives were prepared and assayed in a variety of biological tests for antiviral activity. Also, some of the prepared products were tested for anti-avian influenza virus activity and revealed promising antiviral activity against H5N1 virus by determination of both EC 50 and LD 50 confirmed by the plaque reduction assay on MDCK cells. phenyl)-N-{2,3-dihydro-4-hydroxy-3-phenyl-6-oxo-2-thioxopyrimidin-1(6H)-yl}-5-phenyl--1H-pyrazole-3-carboxamide (12a) showed the highest anti-H5N1 activity of virus reduction varying from 75 % obtained by 10 mg per well to 84 % by 40 mg per well.
